Sensitivity to EGFR inhibitors based on location of EGFR exon 20 insertion mutations within the tyrosine kinase domain of EGFR.

被引：0
|
作者：
Costa, Daniel Botelho
Yasuda, Hiroyuki
Sng, Natasha J.
Yeo, Wee-Lee
de Figueiredo-Pontes, Lorena Lobo
Tenen, Daniel G.
Kobayashi, Susumu
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7523
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations
    Chen, Hao
    Hu, Shiliang
    Patterson, Adam V.
    Smaill, Jeff B.
    Ding, Ke
    Lu, Xiaoyun
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, : 11656 - 11671
  • [32] Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
    Lee, Yusoo
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Soyeon
    Kim, Miso
    Keam, Bhumsuk
    Ku, Ja-Lok
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1556 - 1566
  • [33] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations
    Bazhenova, L.
    Yang, J. Chih-Hsin
    Wang, M.
    Mitchell, P.
    Camidge, D. Ross
    Fang, J.
    Nian, W.
    Chiu, C. -H.
    Zhou, J.
    Zhao, Y.
    Su, W. -C.
    Yang, T. -Y.
    Zhu, V. W.
    Millward, M.
    Fan, Y.
    Huang, W. -T.
    Cheng, Y.
    Jiang, L.
    Zheng, L.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E3 - E3
  • [34] Structural Basis for the Functional Changes by EGFR Exon 20 Insertion Mutations
    Tamirat, Mahlet Z.
    Kurppa, Kari J.
    Elenius, Klaus
    Johnson, Mark S.
    CANCERS, 2021, 13 (05) : 1 - 21
  • [35] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Linardou, Helena
    Dahabreh, Issa J.
    Bafaloukos, Dimitrios
    Kosmidis, Paris
    Murray, Samuel
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (06) : 352 - 366
  • [36] Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
    Helena Linardou
    Issa J. Dahabreh
    Dimitrios Bafaloukos
    Paris Kosmidis
    Samuel Murray
    Nature Reviews Clinical Oncology, 2009, 6 : 352 - 366
  • [37] Sequencing of EGFR Tyrosine Kinase Inhibitors
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S83 - S85
  • [38] Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors
    An, Lei
    Wang, Yueqiang
    Wu, Guangyao
    Wang, Zhenxing
    Shi, Zeyuan
    Liu, Chang
    Wang, Chunli
    Yi, Ming
    Niu, Chenguang
    Duan, Shaofeng
    Li, Xiaodong
    Tang, Wenxue
    Wu, Kongming
    Chen, Shuqing
    Xu, Hongen
    TRANSLATIONAL RESEARCH, 2023, 255 : 14 - 25
  • [39] EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors
    Yang, Guangjian
    Yang, Yaning
    Hu, Jiaqi
    Xu, Haiyan
    Zhang, Shuyang
    Wang, Yan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Location of EGFR exon 20 insertions matters
    Cardona, Andres Felipe
    Gonzalez-Cao, Maria
    Arrieta, Oscar
    Rosell, Rafael
    CANCER CELL, 2022, 40 (07) : 705 - 708
12345